TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32187457
Drug: Selumetinib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (25 mg/m², oral, twice daily, continuous dosing schedule, 28-day cycles)
Study: 32187883
Drug: Clofarabine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofarabine (30 mg/m²)
Study: 32188417
Drug: NEPA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEPA and dexamethasone (12 mg intravenously)
Study: 32188593
Drug: Omega-3 supplement
Normalized name: Systane Vitamin Omega-3 Supplement Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplement (4 g/day eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) as ethyl esters)
Study: 32188593
Drug: Placebo (4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 g/day olive oil)
Study: 32188704
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg administered intravenously every 21 days
Study: 32188971
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LFA and β-D-glucan test
Study: 32190892
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sufficient 25(OH)D3 (≥50 nmol/L) and high magnesium intake
Study: 32191209
Drug: Hypothermic oxygenated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermic oxygenated perfusion (HOPE) with cold Belzer solution (4-10°C) and continuous oxygenation (partial pressure of oxygen of 500-600 mm Hg)
Study: 32191209
Drug: Static cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static cold storage (SCS) with Celsior solution stored on ice
Study: 32191330
Drug: Apatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib plus oral vinorelbine
Study: 32192431
Drug: cis-atracurium 150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis-atracurium 150, 100, 70, 50, 30, and 20 μg·kg
Study: 32192445
Drug: Novel test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel test for assessing the effect of genetic markers on drug immunogenicity
Study: 32192445
Drug: Novel test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel test for analyzing drug immunogenicity
Study: 32192573
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg intravenously over 60 min on days 1 and 15 of a 28-day cycle (part A)
Study: 32192573
Drug: Nivolumab (recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (recommended phase 2 dose) (part B)
Study: 32192746
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) at 12 months
Study: 32195186
Drug: Triplet combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplet combination of Trastuzumab, Lapatinib, and Chemotherapy
Study: 32195932
Drug: Drug-eluting beads
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting beads transarterial chemoembolization (DEB-TACE)
Study: 32197630
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of autologous MSCs (0.5-2 × 10^6 cells) after surgical scar resection
Study: 32197630
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of autologous MSCs
Study: 32200083
Drug: Physicians' meetings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physicians' meetings to optimize bowel preparation
Study: 32200083
Drug: Written and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written and oral instructions to patients
Study: 32200083
Drug: Split-dose regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose regimens
Study: 32200083
Drug: 75% or
Normalized name: Cellulose 75% Oral Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75% or more intake of bowel preparation
Study: 32200083
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of anti-psychotic drugs
Study: 32200138
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg daily until radiological progression or death
Study: 34763195
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg daily
Study: 32201506
Drug: Sorafenib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (200 mg orally twice daily, days 1-5 and 8-12) and Bevacizumab (5 mg/kg intravenously, day 1) every 2 weeks
Study: 32202706
Drug: Total daily
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total daily sitting
Study: 32202706
Drug: Daily sedentary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sedentary time (accelerometer subsample)
Study: 32203069
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg daily for 4-12 weeks
Study: 32203069
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg daily for >50 days
Study: 32203268
Drug: Treosulfan-based conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treosulfan-based conditioning treatment
Study: 32203698
Drug: Pemigatinib 13.5
Normalized name: pemigatinib 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemigatinib 13.5 mg orally once daily (21-day cycle; 2 weeks on, 1 week off)
Study: 32205016
Drug: Capivasertib (AZD5363)
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capivasertib (AZD5363) 320 mg, 400 mg, and 480 mg twice daily (b.i.d.) for 4 days on and 3 days off in combination with enzalutamide 160 mg daily
Study: 32205016
Drug: Capivasertib (AZD5363)
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capivasertib (AZD5363) 400 mg b.i.d. with enzalutamide 160 mg daily
Study: 32205017
Drug: Ipatasertib 600
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib 600 mg combined with paclitaxel
Study: 32205017
Drug: Ipatasertib 600
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib 600 mg combined with mFOLFOX6
Study: 32205017
Drug: Ipatasertib 400
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib 400 mg combined with paclitaxel
Study: 32205017
Drug: Ipatasertib combined
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib combined with chemotherapy or hormonal therapy
Study: 32205128
Drug: Endovenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous laser therapy using a 400-μm optical fiber with a 1470-nm laser
Study: 32205328
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitor therapy
Study: 32206659
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pulmonary recruitment maneuver and intraperitoneal bupivacaine
Study: 32206660
Drug: Oxaloacetate/vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaloacetate/vitamin C (2 capsules of 100 mg oxaloacetate/150 mg ascorbic acid)
Study: 32206660
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules of rice flour)
Study: 32206673
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (2 weeks of unloading in a plaster cast followed by 4 weeks of weightbearing in an orthosis)
Study: 32206973
Drug: Adalimumab therapy
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab therapy for 24 months
Study: 32206976
Drug: Concurrent scalp-sparing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent scalp-sparing radiation (60 Gy in 30 fractions) with standard concurrent temozolomide (75 mg/m2) and tumor treatment fields (TTFields)
Study: 32207164
Drug: Imalumab (oxMIF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imalumab (oxMIF inhibitor) at doses of 1 to 50 mg/kg IV every 2 weeks or 10 or 25 mg/kg IV weekly (1 cycle = 28 days)
Study: 32208121
Drug: Therapeutic adjustment
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic adjustment or treatment switch after pathological ABPM.
Study: 32208121
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of antihypertensive therapy after pathological ABPM.
Study: 32208873
Drug: Molecularly matched
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecularly matched therapy
Study: 32208957
Drug: Ivosidenib (AG-120)
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivosidenib (AG-120) monotherapy
Study: 32209624
Drug: Current systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current systemic or topical treatment for AD (at the discretion of the investigator)
Study: 32210458
Drug: Pre-treatment CD4+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment CD4+ count <350 cells/mm3
Study: 32210527
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravitreal aflibercept (IVT-AFL) every 4 weeks (2q4)
Study: 32210527
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravitreal aflibercept (IVT-AFL) every 8 weeks (2q8)
Study: 32210527
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravitreal aflibercept (IVT-AFL)
Study: 32210906
Drug: Nilvadipine (dihydropyridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine (dihydropyridine calcium channel blocker)
Study: 32211336
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate 300 mg given 2-3 times daily, adjusted to target serum concentration (0.6 to 1.0 mmol/L); Tretinoin 22.5 or 45 mg/m²
Study: 32211756
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of ceftolozane/tazobactam administered q8h
Study: 37154471
Drug: Crisaborole ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole ointment, 2%, applied twice daily for 28 days
Study: 32213344
Drug: Melflufen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melflufen plus dexamethasone (40 mg melflufen, 40 mg dexamethasone weekly)
Study: 32213344
Drug: Single-agent melflufen
Normalized name: Melflufen
DrugBank: Melphalan flufenamide (DB16627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent melflufen
Study: 32214793
Drug: 0.19 mg
Normalized name: zinc oxide 0.19 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.19 mg Fluocinolone Acetonide intravitreal implant
Study: 32217877
Drug: Patient-reported outcome
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-reported outcome measures (PROMs) including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the Outcomes and Experiences Questionnaire
Study: 32218807
Drug: Apatinib (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (first line, second line, and third or higher line therapy)
Study: 32218807
Drug: Apatinib (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (low-dose 250 mg, mid-dose 425-500 mg, high-dose 675-850 mg)
Study: 32219330
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment (MET)
Study: 32219330
Drug: Nonpharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacological treatment (NPT)
Study: 32219421
Drug: Maternal fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal fasting glucose increase (1-mmol/L)
Study: 32219421
Drug: Maternal 2-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal 2-h OGTT glucose increase (1-mmol/L)
Study: 32219431
Drug: Hydrocodone-acetaminophen prescribed
Normalized name: Dolorex Forte (hydrocodone / acetaminophen) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone-acetaminophen prescribed (median 12 pills)
Study: 32220908
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle until disease progression, death, or unacceptable toxicity.
Study: 32221013
Drug: Haploidentical NK
Normalized name: IL15-NK Cell
DrugBank: IL15-NK Cell (DB15725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haploidentical NK cell infusion
Study: 32221099
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of opioids during RSI in adults
Study: 32221099
Drug: First-line medications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line medications for haemodynamically stable adults: propofol
Study: 32221099
Drug: First-line medications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line medications for haemodynamically stable adults: suxamethonium
Study: 32221099
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of opioids during RSI in paediatric patients
Study: 32221099
Drug: First-line medications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line medications for haemodynamically stable children: propofol
Study: 32221099
Drug: First-line medications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line medications for haemodynamically stable children: rocuronium
Study: 32222808
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin (pola) 1.0-1.8 mg/kg administered intravenously every 3 weeks (q3w) with R/G-CHP
Study: 32223740
Drug: mNavigator digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: mNavigator digital health application for protocol compliance in pediatric cancer treatment
Study: 32223937
Drug: Larotrectinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larotrectinib (oral TRK inhibitor)
Study: 32224030
Drug: Non-Glycoprotein IIb/IIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Glycoprotein IIb/IIIa inhibitors (non-GPI)
Study: 32224306
Drug: Lurbinectedin (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurbinectedin (3.2 mg/m²)
Study: 32224416
Drug: Toripalimab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab (10 mg/kg Q2W)
Study: 32225136
Drug: MS-Fit training
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-Fit training program (standardized, ambulatory, hospital-based circuit training) performed two hours, twice weekly, for two months.
Study: 32226634
Drug: Client-centred lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centred lifestyle and behavioural intervention, details on dosage and duration not specified.
Study: 32227570
Drug: Weekly prophylaxis,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly prophylaxis, modified prophylaxis, or episodic treatment
Study: 32228297
Drug: Progression group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progression group (AAA with >10-mL increase in volume)
Study: 32228297
Drug: Stable group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable group (AAA with ≤10-mL increase in volume)
Study: 32231633
Drug: Conventional bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional bone conduction hearing implant system
Study: 32231633
Drug: Less invasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less invasive treatment with new abutment technology
Study: 32232107
Drug: Microcurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcurrent treatment administered at home for 5 mins daily for 4 weeks.
Study: 32232597
Drug: Caffeine-containing supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-containing supplement (200 mg caffeine, 1600 mg β-alanine, 1000 mg quercetin) taken 35 minutes before exercise
Study: 32232740
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) in combination with methotrexate (MTX)
Study: 32232817
Drug: Palivizumab administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palivizumab administration during RSV season
Study: 32233741
Drug: No antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antihypertensive treatment
Study: 32234475
Drug: Mannose receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannose receptor (MR) deficiency
Study: 32234848
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell (DC)-based immunotherapy
Study: 32236406
Drug: Isavuconazole (ISAV)
Normalized name: isavuconazole
DrugBank: Isavuconazole (DB11633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole (ISAV) as primary antifungal prophylaxis (PAP)
Study: 32236525
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of urinary-derived human chorionic gonadotropin (uhCG) in addition to standard immunosuppression
Study: 32236861
Drug: Missense variant
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Missense variant rs17117699 in OMA1 in group without β-blocker use
Study: 32236861
Drug: Missense variant
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Missense variant rs17117699 in OMA1 in group with β-blocker use
Study: 32236861
Drug: Functional analysis
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional analysis of rs17117699-G allele
Study: 32238343
Drug: mDASHNa-CC app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: mDASHNa-CC app
Study: 32238515
Drug: Tacrolimus maintenance
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus maintenance therapy
Study: 32238921
Drug: MRX34 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRX34 with oral dexamethasone premedication, given intravenously daily for 5 days in 3-week cycles.
Study: 32238921
Drug: MRX34 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MRX34 treatment with dexamethasone premedication
Study: 32239971
Drug: e-Device (ava®)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: e-Device (ava®) for self-injection of certolizumab pegol (CZP)
Study: 32240454
Drug: Trastuzumab SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab SC administered at home by a healthcare professional (HCP)
Study: 32240454
Drug: Trastuzumab SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab SC administered at home
Study: 32240629
Drug: Once-weekly rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-weekly rifapentine (900 mg) plus isoniazid (900 mg) for 12 weeks
Study: 32240629
Drug: Dolutegravir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (50 mg daily) for 8 weeks prior to rifapentine-isoniazid
Study: 32240793
Drug: CC-90010 (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90010 (45 mg, 4 days on/24 days off)
Study: 32240793
Drug: CC-90010 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90010 (various doses)
Study: 32240796
Drug: Capmatinib 400
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 400 mg (tablets) or 600 mg (capsules) b.i.d.
Study: 32241317
Drug: Preparation for
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation for end of life factors (knowledge of dementia, social support, feeling supported by healthcare providers, formalized end of life documents, end-of-life discussions)
Study: 32241904
Drug: Microbiota from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microbiota from patients with ESRD transplanted to renal injured germ-free mice or antibiotic-treated rats
Study: 32242035
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity extracorporeal low energy shock wave therapy (LiESWT)
Study: 32242358
Drug: KTE-X19 CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTE-X19 CAR T-cell therapy
Study: 32243960
Drug: NS5A-containing DAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS5A-containing DAA therapy
Study: 32244368
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of unfractionated heparin (UFH)
Study: 32245502
Drug: Bispecific CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bispecific CAR T cell therapy targeting CD19 and CD22
Study: 32246968
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus for atopic dermatitis (used for ≥6 weeks)
Study: 32247041
Drug: Quadrivalent human
Normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent human papillomavirus (qHPV) vaccine
Study: 32247206
Drug: Extreme hypofractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extreme hypofractionated doses of 35 Gy in 5 weekly fractions to the whole prostate gland with an integrated boost up to 50 Gy to the mpMRI-defined tumour(s)